On April 22, 2026 PharmaMar (MSE:PHM) a global leader in the research, development, and commercialization of marine-derived oncology therapies, reported it will be present at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), that will take place between May 29th and June 2nd in Chicago, U.S.A.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company, along with its partners, will present two oral and four poster presentations reflecting data on advancing treatment approaches in difficult-to-treat cancers through late-stage clinical research, real-world evidence and ongoing pipeline innovation.

Analysis from the Phase 3 IMforte trial evaluating Zepzelca (lurbinectedin) plus atezolizumab (Tecentriq) as first-line maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC) will be presented, including quality-adjusted time without symptoms or toxicity, as well as an oral presentation on outcomes across SCLC molecular subtypes.

Epidemiology of SCLC in Spain will be presented in the poster: Sex Specific Trends and Outcomes in Small Cell Lung Cancer: Insights From the Spanish CLARISSE Study (2019–2024) a retrospective study led by ICAPEM (Association for Research on Lung Cancer in Women) on more than 4,400 patients diagnosed with small cell lung cancer (SCLC) in the last six years.

The ASCO (Free ASCO Whitepaper) abstracts are available at: www.asco.org/annual-meeting/abstracts-presentations

Highlighted studies at ASCO (Free ASCO Whitepaper) 2026

PRODUCT TITLE LEAD AUTHOR ABSTRACT
Zepzelca (lurbinectedin) IMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance (1Lm) treatment (Tx) with lurbinectedin (lurbi) + atezolizumab (atezo) vs atezo in extensive-stage small cell lung cancer (ES-SCLC) Hossein Borghaei TYPE: Poster SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8086 POSTER BOARD: 560 DATE: May 31, 9:00 AM-12:00 PM CDT
Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the Phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC) Luis Paz-Ares TYPE: rapid oral SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8014 DATE: May 31, 4:00 pm-6:00 PM CDT
Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study Julia Lynne Glade Bender TYPE: rapid oral SESSION: Sarcoma ABSTRACT: 11518 DATE: May 31, 2026, 4:30PM PM- 6:00 PM CDT
Real-world (RW) effectiveness and safety of lurbinectedin (lurbi) for previously treated extensive-stage small cell lung cancer (ES-SCLC): Final primary and subgroup analysis results of Jazz EMERGE 402 Firas Badin TYPE: Poster SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8079 POSTER BOARD: 553 DATE: May 31, 9:00 AM-12:00 PM CDT
Sex Specific Trends and Outcomes in Small Cell Lung Cancer: Insights From the Spanish CLARISSE Study (2019–2024) Pilar Garrido TYPE: Poster SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8092 POSTER BOARD: 566 DATE: May 31, 9:00 AM-12:00 PM CDT
Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer. Apar Kishor Ganti TYPE: Poster SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8093 POSTER BOARD: 567 DATE: May 31, 9:00 AM-12:00 PM CDT

(Press release, PharmaMar, APR 22, 2026, View Source [SID1234664687])